Finally, a scRNA-seq study of eight patients treated with neoadjuvant PD-1 blockade reported activation of a “latent immune signature” in two cases, marked by increased expression of tumor-inhibitory ligands and signs of T cell activation [21]. This evidence concerns the gene PDCD1 and neoplasm.